Cooperation with the bender Group for the Detection of Micrometastases

The bender Group, 100% owner of medigration GmbH, an established RIS/PACS company, is collaborating with mediaire on the development of AI image recognition software for Ferrotran®. The MRI contrast agent by SPL Medical BV, with the bender group as majority stakeholder, is currently in the final phase of clinical approval studies. With the creation of mdprostate, mediaire brings extensive experience in the development of AI image recognition software for prostate cancer to the partnership.

With Ferrotran®, SPL Medical BV aims to enhance the accuracy of cancer diagnostics by detecting lymph node metastases as small as 2 mm. The detection of such small metastases allows for early identification of prostate cancer, promising improved success in therapeutic measures. To fully leverage this advantage, intelligent image recognition software is crucial, especially when specifically designed to evaluate image data using Ferrotran®.

Markus Steinlein, CEO and Head of Software Development at medigration GmbH, emphasizes this approach: "We are convinced that the combination of an innovative iron-based MRI contrast agent with a high-performance, cloud-based AI solution will benefit the patients under examination. The quality of diagnostics can be significantly enhanced through AI."

mediaire shares this sense of optimism and confidence. The investment in their latest AI solution, mdprostate, is paying off early after the product launch. Dr. Andreas Lemke, CEO of mediaire GmbH, expresses optimism: "We see AI-assisted prostate MRI imaging as a great opportunity for more targeted and effective diagnosis of prostate cancer, benefiting millions of patients. Recently, we established a prominent position in this field with the first fully automatic AI tool. The collaboration with medigration on the deep integration of our two medical products into the PACS/RIS system and the further development for the detection of micrometastases is a significant milestone for mediaire."

The importance of the cooperation in software development is also acknowledged by the manufacturer of the MRI contrast agent. Dr. Jürgen Feuerstein, CEO of SPL Medical, comments: "We are pleased that our majority shareholder, the bender group, is taking this step in developing AI, and we anticipate that the expected benefits of Ferrotran® for the diagnosis and therapy of lymph node metastases in prostate cancer can be further enhanced with this AI software."

Already today, mediaire offers a fully automated end-to-end solution for prostate diagnostics with mdprostate. Sign up to test the solution for free and without obligation.

Solutions

*bald verfügbar 

mediaire GmbH

Möckernstrasse 63
10965 Berlin, Germany

P +49 30 286 490 67
F +49 30 286 490 66

© 2022 mediaire GmbH

WORLD PREMIERE AT ECR 2024

Experience mdprostatethe first fully-automated AI-tool including longitudinal assessment for the evaluation of prostate MRIs.

mediaire GmbH

Möckernstrasse 63
10965 Berlin, Germany

P +49 30 286 490 67
F +49 30 286 490 66

© 2022 mediaire GmbH